Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
According to Rosstat, in February 2017, the consumer price index in Russia was 100.2%, since the beginning of the year - 100.8%. For comparison: in February 2016 this indicator was equal to 100.6%. The consumer price index for medicines in February 2017 was 100.2%, since the beginning of the year - 101.1%, in February 2016 - 104.9%.
According to the Federal Customs Service of Russia, in January 2017, 10.1 thousand tons of pharmaceutical products were imported to Russia in the amount of 517 million US dollars, including 9.2 thousand tons from the far-abroad countries for the amount of 505.6 million US dollars, From the CIS countries - 0,9 thousand tons for the amount of 11,3 million US dollars.
FAS Russia draws attention to the fact that the rules for the formation of lists of medicinal products for medical use and the minimum assortment of medicines required for the provision of medical assistance do not envisage the procedure for retaining or transferring the results of voting of commission members for the next year.
You need to buy medicines from those who prescribe a lower price. The rule of "third extra" when buying drugs and medical products should be abolished. This was stated by the head of the Federal Antimonopoly Service Igor Artemyov.
According to GlobalData analysts, the volume of the Russian pharmaceutical market will exceed $ 38 billion by 2021. In 2016, this figure was equal to $ 20.91 billion. The company's experts believe that the Russian pharmaceutical market is one of the most dynamically developing in the world.
Experiment on the labeling of medicines until regards drugs from the list of "7 Diseases" in 2018 to extend the experiment of the drug from the list of vital and essential drugs (VED). This was reported in the session at the Investment Forum in Sochi, the Russian Minister of Health Veronika Skvortsova.
The Russian government is discussing additional measures to support manufacturers of medicines from the list of VED. Among the proposed measures - subsidies and signing long-term contracts on the production for the purposes of public procurement, he said in an interview with RIA Novosti Deputy Prime Minister Olga Golodets.
Russian Health Care is not yet ready for widespread adoption of risk-sharing system (risk-sharing) in public procurement of drugs, said Head of the Department for Control over Social Sphere and Trade, FAS Russia Timofey Nizhegorodtsev. risk-sharing system requires that the State pays the manufacturer only those medicines which have the expected therapeutic effect.